Form 4 for IBRX ImmunityBio, Inc.
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0001647994-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-02-24 | IBRX | Simon Barry J. | Dir | S - Sale | $12.01 | -75.0K | 2.85M | -3% | -$900.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-24 | S | D | 75,000 | $12.01 | 2,850,821 | D | — | — | (F2) Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $12.00 to $12.025 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |